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A growing body of evidence suggests that successful clin-
ical immunotherapy may depend on mutation-specific
T cell responses. Using whole-exome and RNA sequen-
cing of a resected metastatic deposit from a patient with
triple-negative (ER-, PR-, Her2 non-amplified) breast
cancer, we identified 72 non-synonymous mutations.
Using previously published methods of autologous anti-
gen presentation[1], we identified a novel non-synon-
ymous mutation in a regulator of the Notch signaling
pathway, RBPJ (recombination signal binding protein for
immunoglobulin kappa J region), that encodes a neoanti-
gen specifically recognized by autologous CD4+ tumor
infiltrating lymphocytes. Antigen recognition was
restricted by the Class II DR locus. Deep sequencing or
PCR of all 16 metastases collected at autopsy revealed
that the mutation was ubiquitously present in all samples.
To the best of our knowledge, this represents the first
report of an immunogenic mutation in breast cancer.
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